Ati-angiogenesis against cancer;Anti-angiogenese gegen krebs

Deutsche Apotheker Zeitung

Volumn 143, Issue 1-2, 2003, Pages 54-62

  Medinger, Michael ^a   Drevs, Joachim ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOZYME; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FOLINIC ACID; GEMCITABINE; IMC 1C11; PACLITAXEL; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RPI 4610; SEMAXANIB; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VATALANIB; ZK 22254;

ANEMIA; ANGIOGENESIS; ANOREXIA; ARTHRALGIA; ASTHENIA; ASTROCYTOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DYSPNEA; FATIGUE; HUMAN; INJECTION PAIN; IRRITABILITY; LEUKOPENIA; MELANOMA; MESOTHELIOMA; METASTASIS; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; TOXICITY;

EID: 0037427035     PISSN: 00119857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Marme D: Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. World J. Urol. (1996) 14: 166-174.
2. Folkman J: Angiogenesis-dependent diseases. Semin. Oncol. (2001) 28: 536-542.
3. Folkman J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285: 1182-1186.
4. Thomas KA: Vascular Endothelial Growth Factor, a Potent and Selective Angiogenic Agent. J. Biol. Chem. (1996) 271: 603-606.
5. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. (1999) 13: 9-22.
6. Larrivee B, Karsan A: Signaling pathways induced by vascular endothelial growth factor (Review). Int. J. Mol. Med. (2000) 5: 447-456.
7. Harada S, Thomas KA: Vascular Endothelial Growth Factors. In: Principles of Bone Biology. J. P. Bilezikian, Raisz, L. G. and Rodan, G. A. (Eds.). Academic Press, San Diego (2002): 883-902.
8. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marine D: Migration of Human Monocytes in Response to Vascular Endothelial Growth Factor (VEGF) Is Mediated via the VEGF Receptor flt-1. Blood (1996) 87: 3336-3343.
9. Gabrilovich DI, Chen HL, Girgis KR, et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. (1996) 2: 1096-1103.
10. Veikkola T, Jussila L, Makinen T, et al.: Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. (2001) 20: 1223-1231.
11. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362: 841-844.
12. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J, Martiny-Baron G, Unger C, Marme D: Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60: 4819-4824.
13. Drevs J, Schmidt-Gersbach C., Mross K, Medinger M, Müller M, Steward W, Laurent D, Dugan M, Lee L, Henry A, Marmé D, Unger C: Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in two clinical phase I trials. Proc. ASCO (2002) 21: 85a.
14. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60: 2178-2189.
15. Morgan B, Ball H, Buchert M, et al.: Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Surrogate Marker of Efficacy in a Phase I Trial of a VEGF Receptor Tyrosine Kinase Inhibitor. AACR (2001) 92nd Annual Meeting, (2001): 587a.
16. Fong TA, Shawver LK, Sun L, Tang C, App H, Rowell TJ, Kim YH, Mc Mahon G: SU 5416 is a potent and selective inhibitor of the vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59: 99-106.
17. Stopeck A. Results of a phase I dose-escalating study of the antiangiogenic agent, SU 5416, in patients with advanced malignancies. Proc. ASCO (2000) 19: 802.
18. Gajewski T, Fleckinger S, Stadler W. Phase II study of the antiangiogenic FLK-1 tyrosine kinase inhibitor SU5416 in melanoma: initial results. Proc ASCO (2001) 20: 1436.
19. Mendel DB, Laird AD, Smolich BD, et al.: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Design (2000) 15: 29-41.
20. Mendel DB, Schreck RE, West DC, et al.: The Angiogenesis Inhibitor SU5416 Has Long-lasting Effects on Vascular Endothelial Growth Factor Receptor Phosphorylation and Function. Clin. Cancer Res. (2000) 6: 4848-4858.
21. Kuenen BC, Rosen L, Smit EF, et al.: Dose-Finding and Pharmacokinetic Study of Cisplatin. Gemcitabine, and SU5416 in Patients With Solid Tumors. J. Clin. Invest. (2002) 20: 1657-1667.
22. Mesters RM, Padro T, Bieker R, et al.: Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood (2001) 98: 241-243.
23. Britten C, Rosen L, Kabbinavar F, Rosen P, Mulay M, Hernandez L: Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. Proc. ASCO (2002) 21: 28b.
24. Kuenen B, Ruijter R, Hoekman K, Scigalla P, Giaccone G, Pinedo H. Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies. Proc. ASCO (2002) 21: 110a.
25. Rosen LS, Rosen PJ, Kabbinavar F, et al.: Phase I Experience with SU6668, a Novel Multiple Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Malignancies. 37th Annual ASCO Meeting, San Francisco, CA (2001): 383a.
26. Laird AD, Vajkoczy P, Shawver LK, et al.: SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors. Cancer Res. (2000) 60: 4152-4160.
27. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW: Simultaneous Inhibition of the Receptor Kinase Activity of Vascular Endothelial, Fibroblast, and Platelet-derived Growth Factors Suppresses Tumor Growth and Enhances Tumor Radiation Response. Cancer Res. (2002) 62: 1702-1706.
28. Presenti E, Degrassi A, Marzola P, et al.: Evaluation of the efficacy of an anti-angiogenic compound SU6668 in a xenograft tumor model by dynamic contrast enhanced-MRI (DCR-MRI). Proceedings of the 93rd Annual AACR meeting, San Francisco, CA (2002): 4446a.
29. Louie S, Xin X, Christensen J, et al.: Determination of the pharmacokinetic and pharmacodynamic relationships in mice for SU 11248, a potent and selective inhibitor of the VEGF and PDGF receptors. Proc. AACR (2002): 5355a.
30. Mendel D, Laird A, Xin X, et al.: In vivo anti-tumor and mechanism of action studies of SU11248, a potent and selective inhibitor of the VEGF and PDGF receptors. Proc. AACR (2002): 5349a.
31. Drevs J, Esser N, Marme D: Effect of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma. Proc AACR (2002) 43: 1082.
32. Basser R, Hurwitz H, Barge A, Davis I, DeBoer R, Holden S, McArthur G, McKinley M, Nairn K, Persky M, Rosenthal M, Swaisland H, Eckhardt G: Phase I Pharmacokinetic and Biological Study of the Angio-genesis Inhibitor ZD6474, in Patients with Solid Tumors. Proc. ASCO (2001) 20: 100a.
33. Hennequin LF, Stokes ESE, Thomas AR et al.: Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors. J. Med. Chem. (2002) 45: 1300- 1312.
34. Ciardiello F, Caputo R, Damiano V, et al.: Antitumor effects of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor that is also active against EGF receptor tyrosine kinase. Proc. AACR 93rd Annual Meeting, San Franciso, CA (2002): 5348a.
35. Hurwitz H, Holden SN, Eckhardt SG, et al.: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proceeding of the 38th Annual ASCO meeting, Orlando, FL (2002): 325a.
36. Jani J, Beebe J, Emerson E, et al.: CP-547,632, a novel VEGFR-2 tyrosine kinase inhibitor for cancer therapy. Proc. AACR (2002): 5354a.
37. Karp D, Tolcher A, Healey D, et al.: Preliminary pharmacokinetic (PK) characteristics of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI), CP-547,632 in patients (pts) with advanced solid tumors. Proc. AACR (2002): 2753a.
38. Tolcher A, O'Leary J, DeBono J, et al.: A phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. Proc. ASCO (2002) 21: 334a.
39. Langmuir V, Cobleigh M, Herbst R, Holmgren E, Hurwitz H, Kabbinavar F: Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc. ASCO (2002) 21: 9a
40. Nguyen JT: Vascular endothelial growth factor as a target for cancer gene therapy. Adv. Exp. Med. Biol. (2000) 465: 447-456.
41. Presta L, Chen H, O'Connor S, et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57: 4593-4599.
42. Bergsland E, Fehrenbacher L, Novotny W, Holmgren E, Lieberman G, Kabbinavar F: Bevacizumab (BV) + Chemotherapy (CT) May Improve Survival in Metastatic Colorectal Cancer (MCRC) Subjects with Unfavorable Prognostic Indicators. Proc. ASCO (2001) 20: 2247a.
43. DeVore R, Fehrenbacher L, Herbst R, et al.: A Randomized Phase II Trial Comparing Rhumab VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) Plus Carboplatin/Paclitaxel (CP) to CP Alone in Patients with Stage IIIB/IV NSCLC. Proc. ASCO (2000) 19: 1896a.
44. Yang J, Haworth L, Steinberg S, Rosenberg S, Novotny W: A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. ASCO (2002) 21: 15a.
45. Gordon MS, Margolin K, Talpaz M, et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. (2001) 19: 843-850.
46. Margolin K, Gordon MS, Holmgren E, et al.: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. (2001) 19: 851-856.
47. Posey J, Ng T, Yang B, Khazaeli M, Fox F, Engel J: A phase I trial of an anti-KDR (VEGFR) chimeric antibody in patients with liver metastases in colorectal cancer. Proc. ASCO (2002) 21: 17a.
48. Zhu Z, Rockwell P, Lu D, et al.: Inhibition of vascular endothelial growth factor-induced receptor activation with antikinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res. (1998) 58: 3209-3214.
49. Zhu Z, Lu D, Kotanides H, et al.: Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett. (1999) 136: 203-213.
50. Basche M, Sandler A, Eckhardt S, et al.: Angiozyme, an anti-VEGFR1 ribozyme, carboplatin, and paclitaxel: results of a phase I study. Proc. ASCO, (2001): 445.
51. Parry TJ, Cushman C, Gallegos AM, et al.: Bioactivity of anti-angiogenic ribozymes targeting Fit-1 and KDR mRNA. Nucleic Acids Res. (1999) 27: 2569-2577.
52. Pavco PA, Bouhana KS, Gallegos AM, et al.: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. (2000) 6: 2094-2103.